Financhill
Buy
60

EXAS Quote, Financials, Valuation and Earnings

Last price:
$101.11
Seasonality move :
9.03%
Day range:
$101.10 - $101.39
52-week range:
$38.81 - $101.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.16x
P/B ratio:
7.67x
Volume:
6M
Avg. volume:
7.7M
1-year change:
67.19%
Market cap:
$19.2B
Revenue:
$2.8B
EPS (TTM):
-$5.32

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EXAS
EXACT Sciences Corp.
$810.6M $0.16 20.65% -84.17% $103.67
DGX
Quest Diagnostics, Inc.
$2.7B $2.50 5.05% 21.08% $197.31
FLGT
Fulgent Genetics, Inc.
$81.4M -$0.22 12.03% -53.46% $33.67
GH
Guardant Health, Inc.
$235.7M -$0.49 32.6% -47.07% $100.82
ILMN
Illumina, Inc.
$1.1B $1.17 -0.1% 4.75% $120.11
NTRA
Natera, Inc.
$514.8M -$0.35 21.09% -37.96% $237.05
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EXAS
EXACT Sciences Corp.
$101.25 $103.67 $19.2B -- $0.00 0% 6.16x
DGX
Quest Diagnostics, Inc.
$182.61 $197.31 $20.3B 21.43x $0.80 1.73% 1.90x
FLGT
Fulgent Genetics, Inc.
$28.48 $33.67 $880.4M -- $0.00 0% 2.77x
GH
Guardant Health, Inc.
$105.96 $100.82 $13.8B -- $0.00 0% 14.57x
ILMN
Illumina, Inc.
$127.95 $120.11 $19.6B 28.67x $0.00 0% 4.70x
NTRA
Natera, Inc.
$238.21 $237.05 $32.9B -- $0.00 0% 15.19x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EXAS
EXACT Sciences Corp.
50.33% 1.709 24.46% 2.24x
DGX
Quest Diagnostics, Inc.
46.79% 0.203 30.05% 0.90x
FLGT
Fulgent Genetics, Inc.
0.71% -0.040 1.15% 6.47x
GH
Guardant Health, Inc.
136.47% 1.840 16.98% 2.94x
ILMN
Illumina, Inc.
51.97% 2.433 17.73% 1.04x
NTRA
Natera, Inc.
13.7% 1.342 0.9% 3.03x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EXAS
EXACT Sciences Corp.
$583.9M $16.3M -18.87% -38% 1.91% $190M
DGX
Quest Diagnostics, Inc.
$911M $420M 7.41% 14.33% 14.92% $419M
FLGT
Fulgent Genetics, Inc.
$33.5M -$15.4M -3.9% -3.93% -18.26% $5.1M
GH
Guardant Health, Inc.
$171.6M -$99M -36.05% -8518.58% -37.33% -$45.8M
ILMN
Illumina, Inc.
$732M $231M 14.3% 30.55% 21.33% $253M
NTRA
Natera, Inc.
$384.4M -$97.6M -21.88% -26.6% -16.48% $24.5M

EXACT Sciences Corp. vs. Competitors

  • Which has Higher Returns EXAS or DGX?

    Quest Diagnostics, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of 9.13%. EXACT Sciences Corp.'s return on equity of -38% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
    DGX
    Quest Diagnostics, Inc.
    32.35% $2.15 $13.8B
  • What do Analysts Say About EXAS or DGX?

    EXACT Sciences Corp. has a consensus price target of $103.67, signalling upside risk potential of 2.39%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $197.31 which suggests that it could grow by 8.05%. Given that Quest Diagnostics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Quest Diagnostics, Inc. is more attractive than EXACT Sciences Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    EXACT Sciences Corp.
    3 18 0
    DGX
    Quest Diagnostics, Inc.
    7 9 0
  • Is EXAS or DGX More Risky?

    EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.

  • Which is a Better Dividend Stock EXAS or DGX?

    EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.73% to investors and pays a quarterly dividend of $0.80 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios EXAS or DGX?

    EXACT Sciences Corp. quarterly revenues are $850.7M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. EXACT Sciences Corp.'s net income of -$19.6M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 21.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.16x versus 1.90x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    EXACT Sciences Corp.
    6.16x -- $850.7M -$19.6M
    DGX
    Quest Diagnostics, Inc.
    1.90x 21.43x $2.8B $257M
  • Which has Higher Returns EXAS or FLGT?

    Fulgent Genetics, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -8.12%. EXACT Sciences Corp.'s return on equity of -38% beat Fulgent Genetics, Inc.'s return on equity of -3.93%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
    FLGT
    Fulgent Genetics, Inc.
    39.83% -$0.21 $1.1B
  • What do Analysts Say About EXAS or FLGT?

    EXACT Sciences Corp. has a consensus price target of $103.67, signalling upside risk potential of 2.39%. On the other hand Fulgent Genetics, Inc. has an analysts' consensus of $33.67 which suggests that it could grow by 18.21%. Given that Fulgent Genetics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Fulgent Genetics, Inc. is more attractive than EXACT Sciences Corp..

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    EXACT Sciences Corp.
    3 18 0
    FLGT
    Fulgent Genetics, Inc.
    1 1 0
  • Is EXAS or FLGT More Risky?

    EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Fulgent Genetics, Inc. has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.159%.

  • Which is a Better Dividend Stock EXAS or FLGT?

    EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulgent Genetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Fulgent Genetics, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or FLGT?

    EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Fulgent Genetics, Inc. quarterly revenues of $84.1M. EXACT Sciences Corp.'s net income of -$19.6M is lower than Fulgent Genetics, Inc.'s net income of -$6.8M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Fulgent Genetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.16x versus 2.77x for Fulgent Genetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    EXACT Sciences Corp.
    6.16x -- $850.7M -$19.6M
    FLGT
    Fulgent Genetics, Inc.
    2.77x -- $84.1M -$6.8M
  • Which has Higher Returns EXAS or GH?

    Guardant Health, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -34.97%. EXACT Sciences Corp.'s return on equity of -38% beat Guardant Health, Inc.'s return on equity of -8518.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
    GH
    Guardant Health, Inc.
    64.71% -$0.74 $971.9M
  • What do Analysts Say About EXAS or GH?

    EXACT Sciences Corp. has a consensus price target of $103.67, signalling upside risk potential of 2.39%. On the other hand Guardant Health, Inc. has an analysts' consensus of $100.82 which suggests that it could fall by -4.85%. Given that EXACT Sciences Corp. has higher upside potential than Guardant Health, Inc., analysts believe EXACT Sciences Corp. is more attractive than Guardant Health, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    EXACT Sciences Corp.
    3 18 0
    GH
    Guardant Health, Inc.
    17 0 1
  • Is EXAS or GH More Risky?

    EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.579, suggesting its more volatile than the S&P 500 by 57.876%.

  • Which is a Better Dividend Stock EXAS or GH?

    EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or GH?

    EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. EXACT Sciences Corp.'s net income of -$19.6M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.16x versus 14.57x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    EXACT Sciences Corp.
    6.16x -- $850.7M -$19.6M
    GH
    Guardant Health, Inc.
    14.57x -- $265.2M -$92.7M
  • Which has Higher Returns EXAS or ILMN?

    Illumina, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of 13.85%. EXACT Sciences Corp.'s return on equity of -38% beat Illumina, Inc.'s return on equity of 30.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
    ILMN
    Illumina, Inc.
    67.59% $0.97 $5B
  • What do Analysts Say About EXAS or ILMN?

    EXACT Sciences Corp. has a consensus price target of $103.67, signalling upside risk potential of 2.39%. On the other hand Illumina, Inc. has an analysts' consensus of $120.11 which suggests that it could fall by -6.13%. Given that EXACT Sciences Corp. has higher upside potential than Illumina, Inc., analysts believe EXACT Sciences Corp. is more attractive than Illumina, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    EXACT Sciences Corp.
    3 18 0
    ILMN
    Illumina, Inc.
    7 8 1
  • Is EXAS or ILMN More Risky?

    EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

  • Which is a Better Dividend Stock EXAS or ILMN?

    EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or ILMN?

    EXACT Sciences Corp. quarterly revenues are $850.7M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. EXACT Sciences Corp.'s net income of -$19.6M is lower than Illumina, Inc.'s net income of $150M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.16x versus 4.70x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    EXACT Sciences Corp.
    6.16x -- $850.7M -$19.6M
    ILMN
    Illumina, Inc.
    4.70x 28.67x $1.1B $150M
  • Which has Higher Returns EXAS or NTRA?

    Natera, Inc. has a net margin of -2.3% compared to EXACT Sciences Corp.'s net margin of -14.78%. EXACT Sciences Corp.'s return on equity of -38% beat Natera, Inc.'s return on equity of -26.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    EXACT Sciences Corp.
    68.64% -$0.10 $5B
    NTRA
    Natera, Inc.
    64.91% -$0.64 $1.5B
  • What do Analysts Say About EXAS or NTRA?

    EXACT Sciences Corp. has a consensus price target of $103.67, signalling upside risk potential of 2.39%. On the other hand Natera, Inc. has an analysts' consensus of $237.05 which suggests that it could fall by -0.49%. Given that EXACT Sciences Corp. has higher upside potential than Natera, Inc., analysts believe EXACT Sciences Corp. is more attractive than Natera, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    EXACT Sciences Corp.
    3 18 0
    NTRA
    Natera, Inc.
    12 2 0
  • Is EXAS or NTRA More Risky?

    EXACT Sciences Corp. has a beta of 1.417, which suggesting that the stock is 41.664% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.801%.

  • Which is a Better Dividend Stock EXAS or NTRA?

    EXACT Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EXACT Sciences Corp. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or NTRA?

    EXACT Sciences Corp. quarterly revenues are $850.7M, which are larger than Natera, Inc. quarterly revenues of $592.2M. EXACT Sciences Corp.'s net income of -$19.6M is higher than Natera, Inc.'s net income of -$87.5M. Notably, EXACT Sciences Corp.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EXACT Sciences Corp. is 6.16x versus 15.19x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    EXACT Sciences Corp.
    6.16x -- $850.7M -$19.6M
    NTRA
    Natera, Inc.
    15.19x -- $592.2M -$87.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
51
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 61x

Buy
65
Is AAPL Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 38x

Buy
69
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
47
PSTG alert for Dec 4

Pure Storage, Inc. [PSTG] is up 5.05% over the past day.

Sell
41
SMX alert for Dec 4

SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.

Sell
43
HY alert for Dec 4

Hyster-Yale, Inc. [HY] is up 1.92% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock